Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test EGFR (T790M, L858R, Exon 19 deletion) Screening Test by ddPCR is 10-14 days.

What are the prerequisites for the test EGFR (T790M, L858R, Exon 19 deletion) Screening Test by ddPCR

  • Sample: Tissue biopsy or cytology specimen
  • Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue block or at least 10 unstained slides
  • Specimen Container: Slide mailer or tissue block container
  • Specimen Storage: Room temperature
  • Specimen Stability: Stable at room temperature for up to 1 week
  • Specimen Transport: Protect from extreme temperatures during transport

What are the measure values for the test EGFR (T790M, L858R, Exon 19 deletion) Screening Test by ddPCR

  • T790M: 0.05%
  • L858R: 0.02%
  • Exon 19 deletion: 0.08%

What does this test EGFR (T790M, L858R, Exon 19 deletion) Screening Test by ddPCR identify?

  • EGFR (T790M) mutation: This test identifies a specific mutation in the epidermal growth factor receptor (EGFR) gene known as T790M. This mutation is commonly associated with resistance to certain targeted therapies in patients with non-small cell lung cancer.
  • EGFR (L858R) mutation: This test also identifies another mutation in the EGFR gene called L858R. This mutation is known to be sensitive to certain targeted therapies and may influence treatment decisions for patients with non-small cell lung cancer.
  • Exon 19 deletion: Additionally, this test screens for deletions in exon 19 of the EGFR gene. Deletions in this region can also impact treatment options and prognosis for patients with non-small cell lung cancer.

Why is this test EGFR (T790M, L858R, Exon 19 deletion) Screening Test by ddPCR taken?

This test is performed to screen for mutations in the EGFR gene, specifically the T790M, L858R, and Exon 19 deletion mutations. These mutations are commonly found in patients with non-small cell lung cancer (NSCLC) and are associated with resistance to certain targeted therapies, such as tyrosine kinase inhibitors.

By identifying these mutations through the EGFR (T790M, L858R, Exon 19 deletion) Screening Test using digital droplet polymerase chain reaction (ddPCR), healthcare providers can determine the most appropriate treatment options for patients with NSCLC. This personalized approach to treatment can lead to better outcomes and improved quality of life for patients with this type of cancer.

No FAQs available.

Customer Google Rating